TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05114941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immunosorbent column
Description: Immunoadsorption treatment regimen: the treatment is performed once every 1-3 days, at least 5 times, and the amount of regenerated plasma for each treatment is 1 to 3 times the plasma volume. The immunosorbent column adopts the protein A immunosorbent column.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulin
Description: Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
Study: NCT05166122

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Intelligence
Description: Introduction of digitized system with an AI tool to detect and intrepret the severity of diabetic retinopathy and presence of diabetic macular edema in screening for diabetes patients
Study: NCT05491707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Patients will choose a genre of music from the following list; pop, gospel, classical, jazz, and soul, at the preoperative visit. This will be played on disposable ear phones at a self-selected volume for the duration of the surgical procedure.
Study: NCT04846127

Intervention type: DEVICE
Intervention: CanGaroo Envelope
Description: Utilization of a CanGaroo envelope with the CIED during the participant's CIED implant procedure.
Study: NCT05438082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic Prophylaxis
Description: This trial will contain two arms in which patients will be randomized to receive one dose of either Trimethoprim (if \< 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
Study: NCT06532201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Su jok seed therapy
Description: Su Jok will be applied to the reflection points on the hand based on the painful area of the individual. The painful areas will be determined with the applicator and black pepper seeds will be placed on these areas. Circular massage will be applied to the areas where the seeds are located for 30 minutes.
Study: NCT06015711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxigesic administration
Description: Preoperative Maxigesic IV administration
Study: NCT05053555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high dose rate brachytherapy
Description: diagnostic workup, staging, and treatment per the institution standard of care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high dose rate brachytherapy
Description: reviewing historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021
Study: NCT06156488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus floor augmentation
Description: Maxillary sinus floor augmentation through a lateral window grafted with anorganic bovine bone + polynucleotides and hyaluronic acid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary sinus floor augmentation
Description: Maxillary sinus floor augmentation through a lateral window grafted with anorganic bovine bone
Study: NCT06633133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual ileostomy
Description: A pre-stage ileostomy, anchored under the abdominal wall by a vascular sling or rubber tape through the mesenteric window, is delivered to the outside of the abdomen, where the VI is pulled through the abdominal wall.
Study: NCT06375460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused App Prompt
Description: Prompts are designed to develop knowledge and self-efficacy in diabetes-related health behaviors (capability). The paired glycemic and behavior data will provide the opportunity to reflect and to plan diet or exercise for the following day (self-reflective motivation).
Study: NCT05951816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.
Description: Peptide p5+14 is a pan-amyloid reactive, synthetic 45 L-amino acid polypeptide with a net +12 positive charge that can bind two major components of all extracellular amyloid deposits: (i) hypersulfated heparan sulfate glycosaminoglycans (proteoglycans) and (ii) amyloid fibrils. The polypeptide, labeled with iodine-124, has been shown (study AMY1001) to bind amyloid in all organs including the heart. This study will evaluate a Tc-99m-labeled version of the peptide for gamma imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.
Description: 99mTc-PYP is an FDA-approved, commercially available bone-seeking radiotracer used routinely in nuclear medicine. 99mTC-PYP imaging is used clinically for the diagnosis of cardiac ATTR amyloidosis.
Study: NCT06375460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused App Prompt
Description: Prompts are designed to develop knowledge and self-efficacy in diabetes-related health behaviors (capability). The paired glycemic and behavior data will provide the opportunity to reflect and to plan diet or exercise for the following day (self-reflective motivation).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No App Prompt
Description: No app prompts are designed to assess whether health behaviors are affected without being prompted to reflect and change those behaviors related to glycemic control.
Study: NCT05155969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.
Study: NCT04765020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: moderate to high-intensity exercise
Description: Four parts:~1. Initial consultation with recommendations for general physical activity, brochure with exercise recommendations~2. Once per week multi-modal group-based exercise (endurance, strength, mobility, coordination)~3. Once per week supervised multi-modal individual training session (endurance, strength, mobility, coordination). Intensity: 60-80% of max. HR~4. Activity trackers with individual movement goals that will be adjusted every two weeks
Study: NCT05021185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Mobile Doctor (iMD)
Description: Video educational tool
Study: NCT05351203

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: . Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound,. Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae block
Description: ● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
Study: NCT04991740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-78306358
Description: JNJ-78306358 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-78306358
Description: JNJ-78306358 will be administered.
Study: NCT04890483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: five times, once per day.
Study: NCT06076746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIC Psychotherapeutic Intervention(s) for İneffective Coping
Description: Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
Study: NCT06566053

Intervention type: OTHER
Intervention: Observation
Description: Observation
Study: NCT05260658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFTX-1554
Description: CFTX-1554 is a new chemical entity that binds to the angiotensin II type 2 receptor (AT2R).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFTX-1554
Description: CFTX-1554 is a new chemical entity that binds to the angiotensin II type 2 receptor (AT2R).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CFTX-1554 matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CFTX-1554 matching placebo
Study: NCT06076746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapeutic intervention
Description: Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychotherapeutic intervention
Description: Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
Study: NCT06460727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: task oriented exercise training on dynamic surface
Description: Following exercises will be performed in this group: Make the child bounce on swiss ball, reaching the toy with both hand kept over the head on platform swing, high sitting on swiss ball throwing ball with both hands, reaching the toy with one hand shifting the wait towards reaching side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: task oriented exercise training on static surface
Description: The children in this group will receive following TOET: Sit to stand from various cjair heights , standing and reaching indifferent directions for an object, Stepping forwards, backwards, and sideways onto blocks of various heights, walking forward , backward and sideways, Walking up and down stairs
Study: NCT05226962

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone monoester
Description: A commercial liquid supplement ingested in a dose intended to provide \~0.35 g of ketone monoester per kg body mass of the participant
Study: NCT04718727

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral Placebo tablets one-hour preoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg Olanzapine Tablets
Description: oral 5 mg Olanzapine tablets one-hour preoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Olanzapine Tablets
Description: oral 10 mg Olanzapine tablets one-hour preoperatively
Study: NCT06568848

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EKKO therapy
Description: In this group 6 particepents will be included .the interventions will be given for 10 seconds on each finger tips . the session will be 30 mins. 4 to 5 sessions per week
Study: NCT03051451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination metformin hydrochloride/ fluoxetine 1000/20mg
Description: Group B will receive metformin 1700 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Group C will receive placebo oral tablet; All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition
Study: NCT06568848

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment
Description: In this group 6 participants will be included .: Conservative treatment, which includes ROM isometric exercises (20 repetitions per limb), stretching exercises (10 seconds per limb with 3 repetitions), balance training (standing without belts for 20 minutes), and gait training (walking with a frame). The session will be 30 mins
Study: NCT06193044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Valsartan
Description: Amlodipine 10 mg \&valsartan 160 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine/Valsartan
Description: Amlodipine 10 mg \&valsartan 160 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg &valsartan 160 mg (Exforge)
Description: Amlodipine 10 mg \&valsartan 160 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10 mg &valsartan 160 mg (Exforge)
Description: Amlodipine 10 mg \&valsartan 160 mg
Study: NCT04993287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive continuous remote monitoring with structured escalation pathway
Description: Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and HF care team

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
Description: Surveys and interviews with enrolled participants
Study: NCT06041269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosnilimab
Description: PD-1 agonist antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosnilimab
Description: PD-1 agonist antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosnilimab
Description: PD-1 agonist antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06016231

Intervention type: DEVICE
Intervention: Light Adjustable Lens
Description: The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.
Study: NCT05226962

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A liquid placebo that is volume- and taste-matched to the ketone monoester supplement
Study: NCT05978817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Damon Ultima bracket
Description: It is metal twin bracket with their recommended arch wire

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Damon Ultima bracket
Description: It is metal twin bracket with their recommended arch wire
Study: NCT05060913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA Cream
Description: Effect of 5% Emla cream on pricking pain measured on VAS scale.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzocaine Gel
Description: Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
Study: NCT05996601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational materials would be given to all the participants. They would also be followed up by pharmacist.
Study: NCT06134687

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Submucosal Dissection
Description: Removal of study eligible lesions per endoscopic submucosal dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Submucosal Dissection
Description: Removal of study eligible lesions per endoscopic submucosal dissection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Rigidizing Overtube
Description: Utilization of the Novel Rigidizing Overtube (Pathfinder) to aid in performing colonic endoscopic submucosal dissection
Study: NCT04980066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sticky bone and EDTA
Description: treatment using Sticky bone after EDTA root surface biomodification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sticky bone
Description: treatment using Sticky bone
Study: NCT05065957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D07001-softgel capsules + Xeloda (or TS-1)
Description: D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D07001-softgel capsules + Xeloda (or TS-1)
Description: D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX
Description: intravenous infusion on Day 1 for 14-day cycle
Study: NCT06568406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Examination by a physiotherapist: the first check-up with an examination and a therapeutic intervention with the patient is performed within 24-72 hours after delivery. This is followed by two regular outpatient check-ups by a physiotherapist for the purpose of therapy and education. The second check takes place after 6-8 weeks. And the third check occurs after 10-14 weeks after childbirth. In these three checks, data collection is carried out simultaneously (in order to complete the secondary objective). The patients are examined and monitored by the same physiotherapist.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urogynaecology
Description: Examination by a urogynaecologist this is carried out in the period of 14-18 weeks after childbirth in order to complete the primary objective. Data collection in order to complete the primary objective is done in the period of 14-18 weeks and 12-14 months after delivery (the online method without the need for a physical visit is preferred).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urogynaecology
Description: Examination by a urogynaecologist this is carried out in the period of 14-18 weeks after childbirth in order to complete the primary objective. Data collection in order to complete the primary objective is done in the period of 14-18 weeks and 12-14 months after delivery (the online method without the need for a physical visit is preferred).
Study: NCT06543251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training group (HIIT)
Description: The participants performed HIIT programs for 12 weeks involving walking/running on a treadmill preceded by a 10-min warm-up at low intensity and exercise with high intensity for 1 min at 85%-90% of the maximum heart rate alternating with low intensity at 50%-55% of the maximum heart rate for 2 min, for 24 minutes, and 10-min cool down.
Study: NCT05004727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab
Description: Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: • Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
Study: NCT05166291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort-in injection system
Description: local anesthesia applyed with comfort-in injection system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional anesthesia
Description: local anesthesia applyed with dental syringe
Study: NCT04136834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PT01 (Pegtomarginase)
Description: PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.